

## IF: 1.634

## Asian Pacific Journal of Tropical Medicine





doi: 10.4103/1995-7645.243100

©2018 by the Asian Pacific Journal of Tropical Medicine. All rights reserved.

## Bacillomycin D-like compounds isolated from *Bacillus amyloliquefaciens* HAB-2 are effective against *Burkholderia pseudomallei*

Xun Kang<sup>1,#</sup>, Xin Chen<sup>1,#</sup>, Peng-fei Jin<sup>2</sup>, Xian-hua Qu<sup>1</sup>, Hua Pei<sup>1</sup>, Qing-hui Sun<sup>1</sup>, Su-fang Dong<sup>1</sup>, Wei-guo Miao<sup>2⊠</sup>, Qian-feng Xia<sup>1⊠</sup>

**ABSTRACT** Background: Burkholderia pseudomallei (Bp) is a gram-negative environmental bacterium that causes melioidosis. It has high mortality and relapse rates regardless of powerful antibiotic therapy. Bacterial pathogens display versatile gene expression to adapt to changing surroundings, especially when they are infected by drugs. A cyclic lipopeptide was isolated from Bacillus amyloliquefaciens HAB-2, which is a bacillomycin D-like compound, named as bacillomycin DC. It is a potent fungicide against Colletotrichum gloeosporioides Penz. Methods: We used this kind of bacillomycin DC to be inhibitor of Bp and in order to find out how does it infect the bacterial pathogens. We observed the morphological changes under transmission electron microscope (TEM) and scanning electron microscopy (SEM) when BP is in the minimum inhibitory concentration (MIC) of ceftazidime and bacillomycin DC. Then we used quantificationgene Real-Time PCR (qRT-PCR) to measure the expression of three drug-assistant genes including MexB, qnrS and oprD2, respectively. Results: Bacillomycin DC treatment caused changes in the shape and microstructure, and the bacterial outer membrane were damaged, the leakage of the cell were observed. The expression level of mexb gene was not high until 72h after ceftazidime and bacillomycin DC treatment. Both ceftazidime and bacillomycin DC caused high expression of oprD2, but higher expression level proves that the DC works more efficiently and quickly. Bacillomycin DC increased the expresssion level of bacteria qurS gene in 24 h, which proved this compound injured the DNA helicase and topoisomerase of the bacteria in a short time. The results showed that the bacillomycin DC had better inhibitory effects. We also found out that different mechanism of action between ceftazidime and bacillomycin DC. **Conclusion:** The bacillomycin DC makes bacterial pathogen display more oprD2 and qnrS, which respectively means bacterial pathogen are sensitive to the bacillomycin DC and its DNA gyrase are injured. In short, our study showed for the first time that bacillomycin DC can inhibit Bp in a short time.

**Keywords:** Burkholderia pseudomallei; Bacillomycin DC; Ceftazidime; MIC; Inhibitory effect; Quantitative Real-Time PCR

Article history:
Received 15 September 2018
Received in revised form 20 September 2018
Accepted 26 September 2018
Available online 15 October 2018

#These authors contributed equally to this study.

First author: Xun Kang, Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou 571199,

Qian-feng Xia, Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou 571199, China. E-mail: xiaqianfeng@sina.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 3.0 License, which allows others to remix, tweak and buid upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

## For reprints contact: reprints@medknow.com

©2018 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer- Medknow

How to cite this article: Kang X, Chen X, Jin PF, Qu XH, Pei H, Sun QH, et al. Bacillomycin D-like compounds isolated from *Bacillus amyloliquefaciens* HAB-2 are effective against *Burkholderia pseudomallei*. Asian Pac J Trop Med 2018; 11(10 suppl):33.

<sup>&</sup>lt;sup>1</sup>Laboratory of Tropical Biomedicine and Biotechnology, School of Tropical Medicine and Laboratory Medicine, Hainan Medical University, Haikou 571199, China

<sup>&</sup>lt;sup>2</sup>College of Environment and Plant Protection, Hainan University, Haikou 570228, China

E-mail: kangxun2017@163.com

Corresponding author: Wei-guo Miao, College of Environment and Plant Protection, Hainan University, Haikou 570228. China.

E-mail address: miao@hainu.edu.cn